Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)
The group of cancers that originate in the lymphatic system are known as lymphoma. Lymphoma is broadly classified into two types: Hodgkin lymphoma and non-Hodgkin lymphoma. In 2010, more than 16,887 new cases of Hodgkin lymphoma and 139,507 new cases of non-Hodgkin lymphoma were diagnosed in the top seven markets (the US, the UK, Germany, France, Italy, Spain and Japan). The treatment for Hodgkin lymphoma is dominated by the combination of generic drugs like doxorubicin, bleomycin, vinblastine, dacarbazine, mechlorethamine, etoposide, vincristine, prednisone, cyclophosphamide, procarbazine, chlorambucil, methylprednisolone, cytarabine, cisplatin and dexamethasone. The treatment for non-Hodgkin lymphoma is dominated by Rituxan (rituximab) followed by Velcade (bortezomib), Bexxar (tositumomab and Iodine I 131 tositumomab), Zevalin ([90Y]-ibritumomab tiuxetan), Treanda (bendamustine hydrochloride), Folotyn (pralatrexate) and Mozobil (plerixafor).
- There is a high unmet need, both in Hodgkin lymphoma and non-Hodgkin lymphoma, which demands novel agents with improved efficacy and toxicity profiles. The unmet need is very high particularly in the treatment of relapsed and refractory Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) patients. The relapse rates are 30% and 50% for Hodgkin lymphoma and ALCL respectively with limited treatment options representing a significant unmet need. Autologous stem cell transplantation is the only available treatment for relapsed patients. The survival rates in the relapsed patients are less than a year.
Reasons to buy
- Impact analysis of Brentuximab Vedotin as a First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma) SHOW LESS READ MORE >
3.1 Disease Overview
3.3 Current Therapy Options
3.4 Unmet Need
3.5 Brentuximab Vedotin – First Drug to Treat Relapsed or Refractory Hodgkin Lymphoma and ALCL patients.
3.6 Current Market
4.1.2 Secondary Research
4.1.3 Primary Research
4.1.4 Expert Panel Validation
4.2 Contact Us